drugset / Trial / NCT03836638

The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment

NCT03836638

RandomizedParallel-groupSingle-blindTreatment

Summary

Botulinum toxin is approved by the FDA for the treatment of facial wrinkles. Patients are usually older than 45 years and their main demand is to treat pre-existing facial wrinkles. However with the increasing popularity of this technique, younger patients, aged 25 to 35 years, are now seeking botulinum toxin injection as a preventive measure for rhytides. The usual dose used for the treatment of facial rhytides in a female patient older than 45 years is 50 units. No consensus exists concerning the dose of botulinum toxin that should be used in younger patients. Hypothesis: lower dose of botulinum toxin is sufficient to give good and long lasting results in young patients. The objective of this randomized open-label study is to evaluate the effect of lower doses of Botulinum toxin on the facial rythides in young patients.

Timeline

Start
2019-05-01
Primary completion
2020-12-01
Completion
2020-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin Protein / enzyme biologic 30 iu Other
Subject Botulinum toxin Protein / enzyme biologic 50 iu Other